❤️ How Ozempic, Wegovy and Mounjaro Protect Your Heart — Not Just Your Waistline
🩺 A New Era in Heart & Metabolic Health
Over the past few years, injectable medications like Ozempic, Wegovy, and Mounjaro have revolutionised how we approach weight loss and type 2 diabetes.
But beyond blood sugar and body weight, these treatments are now being recognised for something far more significant — their ability to protect the heart.
At The Wright Practice in Harley Street, we focus on proactive and longevity-based healthcare. Understanding how these medicines work — and who they benefit most — helps us tailor truly individual health plans.
Ozempic® (Semaglutide 0.5–1.0 mg weekly): Diabetes and Heart Protection
Ozempic was originally developed for type 2 diabetes, but large studies have shown it lowers the risk of serious heart events such as heart attack and stroke.
The evidence:
The SUSTAIN-6 trial (published in the New England Journal of Medicine) found that people with type 2 diabetes taking Ozempic had:
25% fewer major cardiovascular events than those on placebo
Fewer non-fatal strokes and heart attacks
Benefits that appeared within the first year and strengthened over time
✅ Takeaway: Ozempic not only helps regulate blood sugar and support weight management — it also protects against cardiovascular disease in those already at risk.
Wegovy® (Semaglutide 2.4 mg weekly): Heart Protection Without Diabetes
Wegovy, which contains the same active ingredient as Ozempic but at a higher dose, is prescribed for weight management.
Until recently, no weight-loss medicine had been proven to actually reduce the risk of heart attack or stroke. That changed with the landmark SELECT trial (2023).
The evidence:
Over 17,000 adults with obesity (BMI ≥27) and established heart disease but no diabetes were studied.
Those taking Wegovy had a 20% lower risk of major heart events (heart attack, stroke, or heart-related death).
Benefits extended beyond weight loss — participants also saw improvements in blood pressure, cholesterol, and inflammation.
✅ Takeaway: Wegovy is now the first weight-loss medication approved by the FDA to reduce cardiovascular risk. For patients with heart disease and excess weight, this is a major step forward in preventive medicine.
Mounjaro® (Tirzepatide): Dual Hormone Innovation
Mounjaro is slightly different — it acts on both GLP-1 and GIP receptors, offering powerful effects on glucose control and weight reduction.
The evidence so far:
The ongoing SURPASS-CVOT study compared Mounjaro with dulaglutide (another GLP-1 medicine). Early data suggest:
Mounjaro is at least as safe for the heart as dulaglutide
There may be a trend toward fewer heart events, but full results are still being analysed
✅ Takeaway: Mounjaro already appears heart-safe, and upcoming data may confirm additional cardiovascular benefits similar to semaglutide.
What This Means for You
These medicines aren’t simply about appearance or numbers on a scale.
They’re part of a whole-body, heart-protective strategy that can:
Reduce inflammation and oxidative stress
Improve insulin sensitivity
Lower blood pressure and cholesterol
Support sustainable, long-term cardiovascular health
At The Wright Practice, we integrate these treatments as part of a comprehensive longevity plan — including nutrition, exercise, hormone optimisation, and advanced blood testing.
💬 In Summary
MedicationMain StudyWho It HelpedHeart ImpactOzempic®SUSTAIN-6Type 2 diabetes↓ 25% heart attacks, strokes, CV deathsWegovy®SELECTObesity + CVD (no diabetes)↓ 20% major heart events (FDA-approved)Mounjaro®SURPASS-CVOTType 2 diabetesHeart-safe, results pending
🌿 The Wright Practice Approach
We believe in treating the whole person, not just one marker.
Whether your goal is longevity, weight optimisation, or cardiovascular prevention, our personalised approach combines the best of modern medical science and lifestyle medicine.
Book a consultation to discuss whether a GLP-1 or GIP treatment could support your long-term health goals.